714 related articles for article (PubMed ID: 33166694)
1. Post-exposure prophylaxis with hydroxychloroquine for the prevention of COVID-19, a myth or a reality? The PEP-CQ Study.
Dhibar DP; Arora N; Kakkar A; Singla N; Mohindra R; Suri V; Bhalla A; Sharma N; Singh MP; Prakash A; Pvm L; Medhi B
Int J Antimicrob Agents; 2020 Dec; 56(6):106224. PubMed ID: 33166694
[TBL] [Abstract][Full Text] [Related]
2. The 'myth of Hydroxychloroquine (HCQ) as post-exposure prophylaxis (PEP) for the prevention of COVID-19' is far from reality.
Dhibar DP; Arora N; Chaudhary D; Prakash A; Medhi B; Singla N; Mohindra R; Suri V; Bhalla A; Sharma N; Singh MP; Lakshmi PVM; Goyal K; Ghosh A
Sci Rep; 2023 Jan; 13(1):378. PubMed ID: 36611040
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
[TBL] [Abstract][Full Text] [Related]
4. Hydroxychloroquine for post-exposure prophylaxis of COVID-19 among naval personnel in Sri Lanka: study protocol for a randomized, controlled trial.
Niriella MA; Ediriweera DS; De Silva AP; Premarathne R; Balasooriya P; Duminda KD; Malavige NG; Wanigasuriya K; Lekamwasam S; Kularathne SA; Siribaddana S; de Silva HJ; Jayasinghe S
Trials; 2020 Aug; 21(1):748. PubMed ID: 32854751
[TBL] [Abstract][Full Text] [Related]
5. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
[TBL] [Abstract][Full Text] [Related]
6. Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial.
Barnabas RV; Brown ER; Bershteyn A; Stankiewicz Karita HC; Johnston C; Thorpe LE; Kottkamp A; Neuzil KM; Laufer MK; Deming M; Paasche-Orlow MK; Kissinger PJ; Luk A; Paolino K; Landovitz RJ; Hoffman R; Schaafsma TT; Krows ML; Thomas KK; Morrison S; Haugen HS; Kidoguchi L; Wener M; Greninger AL; Huang ML; Jerome KR; Wald A; Celum C; Chu HY; Baeten JM;
Ann Intern Med; 2021 Mar; 174(3):344-352. PubMed ID: 33284679
[TBL] [Abstract][Full Text] [Related]
7. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19).
Shah S; Das S; Jain A; Misra DP; Negi VS
Int J Rheum Dis; 2020 May; 23(5):613-619. PubMed ID: 32281213
[TBL] [Abstract][Full Text] [Related]
8. Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial.
Lother SA; Abassi M; Agostinis A; Bangdiwala AS; Cheng MP; Drobot G; Engen N; Hullsiek KH; Kelly LE; Lee TC; Lofgren SM; MacKenzie LJ; Marten N; McDonald EG; Okafor EC; Pastick KA; Pullen MF; Rajasingham R; Schwartz I; Skipper CP; Turgeon AF; Zarychanski R; Boulware DR
Can J Anaesth; 2020 Sep; 67(9):1201-1211. PubMed ID: 32383125
[TBL] [Abstract][Full Text] [Related]
9. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
[TBL] [Abstract][Full Text] [Related]
10. Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection.
Infante M; Ricordi C; Alejandro R; Caprio M; Fabbri A
Expert Rev Anti Infect Ther; 2021 Jan; 19(1):5-16. PubMed ID: 32693652
[TBL] [Abstract][Full Text] [Related]
11. Prophylaxis for COVID-19: a systematic review.
Smit M; Marinosci A; Agoritsas T; Calmy A
Clin Microbiol Infect; 2021 Apr; 27(4):532-537. PubMed ID: 33476807
[TBL] [Abstract][Full Text] [Related]
12. A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19.
Mitjà O; Corbacho-Monné M; Ubals M; Alemany A; Suñer C; Tebé C; Tobias A; Peñafiel J; Ballana E; Pérez CA; Admella P; Riera-Martí N; Laporte P; Mitjà J; Clua M; Bertran L; Sarquella M; Gavilán S; Ara J; Argimon JM; Cuatrecasas G; Cañadas P; Elizalde-Torrent A; Fabregat R; Farré M; Forcada A; Flores-Mateo G; López C; Muntada E; Nadal N; Narejos S; Nieto A; Prat N; Puig J; Quiñones C; Ramírez-Viaplana F; Reyes-Urueña J; Riveira-Muñoz E; Ruiz L; Sanz S; Sentís A; Sierra A; Velasco C; Vivanco-Hidalgo RM; Zamora J; Casabona J; Vall-Mayans M; González-Beiras C; Clotet B;
N Engl J Med; 2021 Feb; 384(5):417-427. PubMed ID: 33289973
[TBL] [Abstract][Full Text] [Related]
13. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
[TBL] [Abstract][Full Text] [Related]
14. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.
Boulware DR; Pullen MF; Bangdiwala AS; Pastick KA; Lofgren SM; Okafor EC; Skipper CP; Nascene AA; Nicol MR; Abassi M; Engen NW; Cheng MP; LaBar D; Lother SA; MacKenzie LJ; Drobot G; Marten N; Zarychanski R; Kelly LE; Schwartz IS; McDonald EG; Rajasingham R; Lee TC; Hullsiek KH
N Engl J Med; 2020 Aug; 383(6):517-525. PubMed ID: 32492293
[TBL] [Abstract][Full Text] [Related]
15. Systematic review and meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19.
García-Albéniz X; Del Amo J; Polo R; Morales-Asencio JM; Hernán MA
Eur J Epidemiol; 2022 Aug; 37(8):789-796. PubMed ID: 35943669
[TBL] [Abstract][Full Text] [Related]
16. COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine.
de Barros CM; Almeida CAF; Pereira B; Costa KCM; Pinheiro FA; Maia LDB; Trindade CM; Garcia RCT; Torres LH; Diwan S; Boralli VB
Pain Physician; 2020 Aug; 23(4S):S351-S366. PubMed ID: 32942793
[TBL] [Abstract][Full Text] [Related]
17. Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals?
Lee SH; Son H; Peck KR
Int J Antimicrob Agents; 2020 Jun; 55(6):105988. PubMed ID: 32305587
[TBL] [Abstract][Full Text] [Related]
18. Serosurvey for Health-Care Workers Provides Supportive Evidence for the Effectiveness of Hydroxychloroquine Prophylaxis against SARS-CoV-2 Infection.
Yadav RM; Pate A; Shankarkumar A; Athalye S; Shinde S; Bargir UA; Pate M; Ganpule M; Pruthi M; Patil H; Madkaikar MR
J Epidemiol Glob Health; 2021 Sep; 11(3):283-288. PubMed ID: 34514761
[TBL] [Abstract][Full Text] [Related]
19. Hydroxychloroquine to prevent SARS-CoV-2 infection among healthcare workers: early termination of a phase 3, randomised, open-label, controlled clinical trial.
Llanos-Cuentas A; Schwalb A; Quintana JL; Delfin B; Alvarez F; Ugarte-Gil C; Guerra Gronerth RI; Lucchetti A; Grogl M; Gotuzzo E
BMC Res Notes; 2023 Feb; 16(1):22. PubMed ID: 36849996
[TBL] [Abstract][Full Text] [Related]
20. ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.
McEniery CM; Fisk M; Miles K; Kaloyirou F; Hubsch A; Smith J; Wilkinson IB; Cheriyan J
Trials; 2020 Jul; 21(1):604. PubMed ID: 32616067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
